Watson’s Generic Lovenox Launches At Risk; Will Sanofi’s Authorized Generic Follow?
This article was originally published in The Pink Sheet Daily
Executive Summary
An appeals court lifted a preliminary injunction that blocked Amphastar and U.S. marketing partner Watson from selling their generic version of Sanofi’s blood thinner. Watson is to launch immediately in the U.S.
You may also be interested in...
Woodcock Faces Maze Of Rules To Become Commissioner Nominee
If Biden administration wants to nominate the acting commissioner, Vacancies Reform Act would dictate the timing. Woodcock can still get the nod and remain head of the agency during the confirmation process, just as Andrew von Eschenbach retained his acting title following his nomination in 2006.
FTC Commissioner Changes Could Impact Pharma Mergers, Scrutiny Of Biosimilars Uptake
President Biden’s picks to fill two commissioner posts may shift dynamics on pharmaceutical industry enforcement. Rohit Chopra’s nomination to Consumer Financial Protection Bureau removes strong critic of pharma mergers.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: